2025Year8Month28Day，GEHealthcare (NASDAQ:GEHC) Launches Its Latest CardiologyAIProduct, aimed at comprehensively improving the workflow of cardiovascular disease diagnosis and treatment.This innovative achievement in2025European Society of Cardiology (ESC) made a brilliant appearance at the conference, drawing widespread attention from the industry.

This innovative suite focuses on enhancing clinical decision-making, improving workflow efficiency, and supporting cardiovascular disease (CVD) Early Diagnosis and Treatment，Including four AI-enhanced products, respectivelyViewPoint EchoPilot、CardIQ Suite、Revolution VibeAndComboLab AltiX AI.i。

• ViewPoint EchoPilot: Intelligent-Driven Ultrasound Workflow Revolution

ViewPoint EchoPilotAs an AI-driven workflow solution, it automates echo measurements and reporting. Its cloud-based architecture features robust image recognition, viewing, and tagging capabilities, accurately capturing clinical findings and relevant computational data while automatically generating comprehensive reports. The entire process requires no manual clicks, significantly boosting efficiency, reducing human error, and saving clinicians considerable time and effort.

• CardIQ Suite: A Powerful Assistant for Advanced Cardiac Imaging Analysis

CardIQ SuitePost-processing applications focus on advanced cardiac imaging analysis, providing strong support for the reliable diagnosis of coronary artery disease and myocardial function. Its unique fully automatic calcium scoring algorithm can quickly identify calcium burden and its location, providing the total score and detailed scores for each region within seconds. In addition, the application also features visualization and estimation of cardiac fat volume, offering clinicians more comprehensive information on heart health to assist in precise diagnosis and the development of personalized treatment plans.

• Revolution Vibe: Next GenerationCTSystem Excellence

Revolution VibeAs the next generationCTSystem, with unlimited single-shot cardiac imaging capabilities, and integrated embeddedAITool. Within a single heartbeat, it can provide high-quality coronary artery imaging.CTAngiography (CCTA) images, while significantly reducing the scanning time by up to50%. This breakthrough technology not only enhances image quality but also significantly reduces examination time for patients, lowers the risk of radiation exposure, and provides a more efficient and safer method for the early screening and diagnosis of cardiovascular diseases.

• ComboLab AltiX: Innovative Fusion of Integrated Electrophysiology and Hemodynamic Recording

ComboLab AltiXYesGEHealthcare in Integrated Electrophysiology (EP) and the latest achievements in hemodynamic recording systems were obtained earlier this year.CELogo. The system showcasesGEHealthcare andVolta MedicalDeep cooperation throughVoltaInterface UtilizationPruckaStreamShare real-time data forVolta AF-XplorerDecision Support Systems Provide Critical Information. This innovative integration offers more comprehensive and real-time data support for electrophysiology research and clinical treatment, helping to improve the diagnosis and treatment of cardiovascular diseases such as arrhythmia.

GE HealthCarePresident and CEO of Advanced Visualization SolutionsPhil RackliffeCardiovascular disease continues to impose a heavy and increasingly burdensome impact on global health systems, clinicians, and patients. InESC"At the conference, by showcasing these innovative achievements, we demonstrated our firm commitment to empowering nursing teams through technological innovation. These intelligently connected tools are designed to streamline workflows, accelerate the diagnostic process, and set new standards in cardiac imaging, with the ultimate goal of improving patient outcomes at every stage of cardiac disease diagnosis and treatment."

This timeGEGE Healthcare's innovative cardiology suite, with its advanced artificial intelligence technology and innovative design concepts, has brought new breakthroughs and opportunities to the diagnosis and treatment of cardiovascular diseases. It is expected to further advance the field of biomedical engineering in cardiology, bringing more benefits to cardiovascular patients worldwide.